Arbor Biotechnologies and 4DMT — two U.S. companies working in next-generation genetic medicines — have established a strategic partnership to develop and commercialize novel gene therapies for neurological diseases, including amyotrophic lateral sclerosis (ALS). The agreement includes the codevelopment of up to six product candidates for diseases…
PharmAust announced that it soon will engage with U.S. Food and Drug Administration (FDA) regulators regarding development plans for monepantel, its investigational therapy for amyotrophic lateral sclerosis (ALS) and motor neuron disease (MND). If the pre-investigational new drug meeting goes well, the company intends to file a…
BrainStorm Cell Therapeutics has received patents in Europe, Australia, and Israel covering the use of investigational NurOwn and NurOwn exosomes in treating amyotrophic lateral sclerosis (ALS) and other neurological disorders. The European patent specifically covers the use of an isolated population of mesenchymal stem cells —…
A previously unknown mutation in the SPTLC2 gene was identified in two patients who developed juvenile-onset amyotrophic lateral sclerosis (ALS), a study reports. The mutation significantly increased the production of certain types of fat-like molecules called sphingolipids, resulting in early-onset muscle weakness, progressive motor impairment, and involuntary tongue movements.
Researchers have developed an algorithm to generate personalized survival predictions for people with amyotrophic lateral sclerosis (ALS) based on clinical and MRI features. The scientists believe the algorithm could help patients and doctors make better treatment and care plans. “The disease progression varies greatly for ALS patients, so it…
Axoltis Pharma‘s new treatment candidate for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases was deemed safe and well tolerated at multiple doses in healthy volunteers who participated in a Phase 1b trial. Findings from the trial and preclinical studies also indicate NX210c is working as intended, boosting…
Throughout 2023, ALS News Today brought you daily coverage of the latest clinical research and scientific breakthroughs related to amyotrophic lateral sclerosis (ALS). Here are the year’s top 10 most-read articles, each with a brief description. We’re excited to remain a dependable resource for the ALS community in…
Exposure to certain toxic airborne chemicals used in industry significantly increases — by up to six times — the odds of developing amyotrophic lateral sclerosis (ALS), a study suggests. Findings underscore the importance of surveillance programs testing exposure to these airborne pollutants, especially among populations at risk. The study,…
Transcranial stimulation — a noninvasive technique that delivers low electrical currents to the brain to fine-tune nerve cell activity — improved muscle strength and quality of life in people with amyotrophic lateral sclerosis (ALS) in a small clinical trial. Researchers also found that a two-week course of transcranial direct…
People with negative responses to a tuberculin skin test a few years after being vaccinated against tuberculosis had a significant, 25% lower risk of developing amyotrophic lateral sclerosis (ALS) in their lifetime, according to a study in Norway. Because a positive reaction is linked to the recruitment of T…
